newsfilter
← Latest News
PR Newswire·

Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

SUMMIT, N.J., Sept. 29, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines from